Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31652177 | 0.89 | LPL (0.40) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL264121 | 0.87 | LPL (0.39) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL268040 | 0.86 | LPL (0.38) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL16049143 | 0.85 | LPL (0.41) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL22320285 | 0.84 | ACHE (0.33) | LPLLIPGEGFR | |
| SCHEMBL29686713 | 0.83 | LPL (0.45) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL6691405 | 0.83 | LPL (0.45) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL31753982 | 0.82 | EGFR (0.36) | LPLLIPGEGFR | |
| SCHEMBL4259193 | 0.82 | LPL (0.38) | LPLLIPGEGFRCXCR2 | |
| SCHEMBL29605546 | 0.82 | LPL (0.38) | LPLLIPGEGFRCXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | LPL 2188/4885LIPG 2472/4885EGFR 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.